Patents by Inventor Guoqin FAN

Guoqin FAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted pyrrolizines for the treatment of hepatitis B
    Patent number: 11591334
    Abstract: The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having a structure shown by the following formula (A1): or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate, or a solvate thereof, that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: February 28, 2023
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Guoqin Fan, Cenbin Lu, Sai Yang, Xiaoguang Wang
  • JAK kinase inhibitor and preparation method and use thereof
    Patent number: 11524961
    Abstract: Provided is a selective JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, provided is a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: December 13, 2022
    Assignee: SHANGHAI LONGWOOD BIOPHARMACEUTICALS CO., LTD.
    Inventors: Zhe Wang, Guoqin Fan, Sai Yang, Zhihong Zeng
  • BICYCLIC NUCLEOCAPSID INHIBITOR AND USE OF SAME AS DRUG IN TREATMENT OF HEPATITIS B
    Publication number: 20200354366
    Abstract: The present invention relates to a bicyclic nucleocapsid inhibitor and the use of the same as a drug in the treatment of hepatitis B. In particular, disclosed is a compound having the structure as shown in chemical formula A, or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof that can be used as an HBV inhibitor, wherein the definition of each group is as described in detail in the description. The present invention also relates to a pharmaceutical composition comprising the compound and the use of the same in the treatment of hepatitis B.
    Type: Application
    Filed: May 4, 2018
    Publication date: November 12, 2020
    Inventors: Zhe WANG, Guoqin FAN, Cenbin LU, Sai YANG, Xiaoguang WANG
  • JAK KINASE INHIBITOR AND PREPARATION METHOD AND USE THEREOF
    Publication number: 20190382408
    Abstract: Provided is a selective JAK kinase selective inhibitor and a preparation method and the use thereof. In particular, provided is a compound having the structure as shown in chemical formula (I) as a JAK kinase inhibitor or a stereoisomer or a tautomer thereof, or a pharmaceutically acceptable salt, a hydrate or a solvate thereof.
    Type: Application
    Filed: January 23, 2018
    Publication date: December 19, 2019
    Inventors: Zhe WANG, Guoqin FAN, Sai YANG, Zhihong ZENG